Iceland vs Mozambique: Access to anti-retroviral drugs, female
Iceland
86.0%
in 2024
Mozambique
85.0%
in 2024
Iceland rank
47th
Mozambique rank
49th
Access to anti-retroviral drugs, female over time
- Iceland
- Mozambique
How they compare
Iceland currently reports 86.0% against 85.0% in Mozambique, a difference of 1.0%.
Across all 25 years both countries report, Iceland has been ahead every year.
Iceland ranks 47th and Mozambique ranks 49th of 141 countries.
Iceland has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Iceland | Mozambique | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 63.4% | 3.4% | 60.0% | Iceland |
| 2010s | 84.0% | 41.4% | 42.6% | Iceland |
| 2020s | 83.6% | 76.6% | 7.0% | Iceland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Iceland or Mozambique?
- Iceland, at 86.0% against 85.0% in Mozambique as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Iceland and Mozambique?
- 1.0%, with Iceland ahead.
- How many years of comparable data are there for Iceland and Mozambique?
- 25 years are reported by both, from 2000 to 2024.
- How do Iceland and Mozambique rank globally for access to anti-retroviral drugs, female?
- Iceland ranks 47th and Mozambique ranks 49th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.